- Home
- EAF vs RLMD Comparison
EAF vs RLMD Comparison
Compare EAF & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EAF | RLMD |
|---|---|---|
| Founded | 1886 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 332.0M | 307.3M |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | EAF | RLMD |
|---|---|---|
| Price | $16.87 | $4.06 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $14.25 | $5.50 |
| AVG Volume (30 Days) | 185.1K | ★ 1.2M |
| Earning Date | 10-24-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $521,894,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $11.64 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.50 | $0.24 |
| 52 Week High | $22.60 | $5.12 |
Technical Indicators
Market Signals| Indicator | EAF | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 66.80 | 58.75 |
| Support Level | $13.80 | $3.70 |
| Resistance Level | $17.49 | $4.56 |
| Average True Range (ATR) | 1.04 | 0.48 |
| MACD | 0.50 | -0.09 |
| Stochastic Oscillator | 92.66 | 23.94 |
Price Performance
Historical ComparisonAbout EAF GrafTech International Ltd.
GrafTech International Ltd is a manufacturer of high-quality graphite electrode products essential to the production of EAF steel and other ferrous and non-ferrous metals. The company has only reportable segment, Industrial Materials, is comprised of its two product categories: graphite electrodes and petroleum needle coke products. Petroleum needle coke is key raw material used in the production of graphite electrodes.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.